Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls

Bibliography

• 1  Carswell EA, Old LJ, Kassel RL et al.: An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl Acad. Sci. USA72(9),3666–3670 (1975).
  Medline CASGoogle Scholar
• 2  Bazzoni F, Beutler B: The tumor necrosis factor ligand and receptor families. N. Engl. J. Med.334(26),1717–1725 (1996).
  Medline CASGoogle Scholar
• 3  Kollias G, Kontoyiannis D: Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev.13(4–5),315–321 (2002).
  Medline CASGoogle Scholar
• 4  Pfeffer K: Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev.14(3–4),185–191 (2003).
  Medline CASGoogle Scholar
• 5  Feldmann M, Maini RN: Discovery of TNF-α as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. Joint Bone Spine69(1),12–18 (2002).
  MedlineGoogle Scholar
• 6  Knight DM, Trinh H, Le J et al.: Construction and initial characterization of a mouse–human chimeric anti-TNF antibody. Mol. Immunol.30(16),1443–1453 (1993).
  Medline CASGoogle Scholar
• 7  Tracey D, Klareskog L, Sasso EH et al.: Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther.117(2),244–279 (2008).
  Medline CASGoogle Scholar
• 8  Remicade^® (infliximab), prescribing information. Centocor, Inc., PA, USA (2006).
  Google Scholar
• 9  Wong M, Ziring D, Korin Y et al.: TNF α blockade in human diseases: mechanisms and future directions. Clin. Immunol.126(2),121–136 (2007).
  MedlineGoogle Scholar
• 10  Enbrel^® (etanercept), prescribing information. Immunex Corp., CA, USA (2007).
  Google Scholar
• 11  Humira (adalimumab), prescribing information. Abbott Laboratories, IL, USA (2007).
  Google Scholar
• 12  Sands BE: Why do anti-tumor necrosis factor antibodies work in Crohn’s disease? Rev. Gastroenterol. Disord.4(Suppl. 3),S10–S17 (2004).
  MedlineGoogle Scholar
• 13  Tak PP: Effects of infliximab treatment on rheumatoid synovial tissue. J. Rheumatol. Suppl.74,31–34 (2005).
  Medline CASGoogle Scholar
• 14  Smeets TJ, Kraan MC, van Loon ME et al.: Tumor necrosis factor α blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum.48(8),2155–2162 (2003).
  Medline CASGoogle Scholar
• 15  Catrina AI, Trollmo C, af Klint E et al.: Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum.52(1),61–72 (2005).
  Medline CASGoogle Scholar
• 16  Vigna-Pérez M, Abud-Mendoza C, Portillo-Salazar H et al.: Immune effects of therapy with adalimumab in patients with rheumatoid arthritis. Clin. Exp. Immunol.141(2),372–380 (2005).
  Medline CASGoogle Scholar
• 17  ten Hove T, van Montfrans C, Peppelenbosch MP et al.: Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease. Gut50(2),206–211 (2002).
  Medline CASGoogle Scholar
• 18  Di Sabatino A, Ciccocioppo R, Cinque B et al.: Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn’s disease. Gut53(1),70–77 (2004).
  Medline CASGoogle Scholar
• 19  Lügering A, Schmidt M, Lügering N et al.: Infliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-dependent pathway. Gastroenterology121(5),1145–1157 (2001).
  Medline CASGoogle Scholar
• 20  Goedkoop AY, Kraan MC, Picavet DI et al.: Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res. Ther.6(4),R326–R334 (2004).
  Medline CASGoogle Scholar
• 21  Krüger-Krasagakis S, Galanopoulos VK, Giannikaki L et al.: Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis. Br. J. Dermatol.154(3),460–466 (2006).
  MedlineGoogle Scholar
• 22  Malaviya R, Sun Y, Tan JK et al.: Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients. J. Am. Acad. Dermatol.55(4),590–597 (2006).
  MedlineGoogle Scholar
• 23  Malaviya R, Sun Y, Tan JK et al.: Induction of lesional and circulating leukocyte apoptosis by infliximab in a patient with moderate to severe psoriasis. J. Drugs Dermatol.5(9),890–893 (2006).
  MedlineGoogle Scholar
• 24  Schottelius AJ, Moldawer LL, Dinarello CA et al.: Biology of tumor necrosis factor-α – implications for psoriasis. Exp. Dermatol.13(4),193–222 (2004).
  Medline CASGoogle Scholar
• 25  Charles P, Elliott MJ, Davis D et al.: Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J. Immunol.163(3),1521–1528 (1999).
  Medline CASGoogle Scholar
• 26  Pittoni V, Bombardieri M, Spinelli FR et al.: Anti-tumour necrosis factor (TNF) α treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13. Ann. Rheum. Dis.61(8),723–725 (2002).
  Medline CASGoogle Scholar
• 27  Ulfgren AK, Andersson U, Engström M et al.: Systemic anti-tumor necrosis factor α therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor α synthesis. Arthritis Rheum.43(11),2391–2396 (2000).
  Medline CASGoogle Scholar
• 28  Schotte H, Schlüter B, Willeke P et al.: Long-term treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritis. Rheumatology (Oxford)43(8),960–964 (2004).
  Medline CASGoogle Scholar
• 29  Zou J, Rudwaleit M, Brandt J et al.: Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum.48(3),780–790 (2003).
  Medline CASGoogle Scholar
• 30  Zou J, Rudwaleit M, Brandt J et al.: Up regulation of the production of tumour necrosis factor α and interferon-γ by T cells in ankylosing spondylitis during treatment with etanercept. Ann. Rheum. Dis.62(6),561–564 (2003).
  Medline CASGoogle Scholar
• 31  Rudwaleit M, Siegert S, Yin Z et al.: Low T cell production of TNFα and IFNγ in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Ann. Rheum. Dis.60(1),36–42 (2001).
  Medline CASGoogle Scholar
• 32  Rudwaleit M, Andermann B, Alten R et al.: Atopic disorders in ankylosing spondylitis and rheumatoid arthritis. Ann. Rheum. Dis.61(11),968–974 (2002).
  Medline CASGoogle Scholar
• 33  Gottlieb AB, Chamian F, Masud S et al.: TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J. Immunol.175(4),2721–2729 (2005).
  Medline CASGoogle Scholar
• 34  Taylor PC, Peters AM, Paleolog E et al.: Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis. Arthritis Rheum.43(1),38–47 (2000).
  Medline CASGoogle Scholar
• 35  van Deventer SJ: Tumour necrosis factor and Crohn’s disease. Gut40(4),443–448 (1997).
  Medline CASGoogle Scholar
• 36  Markham T, Mullan R, Golden-Mason L et al.: Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. J. Am. Acad. Dermatol.54(6),1003–1012 (2006).
  MedlineGoogle Scholar
• 37  Aggarwal A, Panda S, Misra R: Effect of etanercept on matrix metalloproteinases and angiogenic vascular endothelial growth factor: a time kinetic study. Ann. Rheum. Dis.63(7),891–892 (2004).
  Medline CASGoogle Scholar
• 38  Cordiali-Fei P, Trento E, D’Agosto G et al.: Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-α. J. Autoimmune Dis.3,5 (2006).
  MedlineGoogle Scholar
• 39  Curran S, Murray GI: Matrix metalloproteinases in tumour invasion and metastasis. J. Pathol.189(3),300–308 (1999).
  Medline CASGoogle Scholar
• 40  Maini RN, Taylor PC: Anti-cytokine therapy for rheumatoid arthritis. Ann. Rev. Med.51,207–229 (2000).
  Medline CASGoogle Scholar
• 41  Firestein GS: Etiology and pathogenesis of rheumatoid arthritis. In: Textbook of Rheumatology (5th Edition). Kelley WN, Harris ED Jr, Ruddy S, Sledge CB (Eds). WB Saunders, PA, USA, 851–897 (1997).
  Google Scholar
• 42  Ishiguro N, Ito T, Obata K et al.: Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis. J. Rheumatol.23,1599–1604 (1996).
  Medline CASGoogle Scholar
• 43  Zucker S, Lysik RM, Zarrabi MH et al.: Elevated plasma stromelysin levels in arthritis. J. Rheumatol.21,2329–2333 (1994).
  Medline CASGoogle Scholar
• 44  Catrina AI, Lampa J, Ernestam S et al.: Anti-tumour necrosis factor (TNF)-α therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology (Oxford)41(5),484–449 (2002).
  Medline CASGoogle Scholar
• 45  Brennan FM, Browne KA, Green PA et al.: Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-α (cA2) therapy. Br. J. Rheumatol.36,643–650 (1997).
  Medline CASGoogle Scholar
• 46  Kruithof E, De Rycke L, Roth J et al.: Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum.52(12),3898–3909 (2005).
  Medline CASGoogle Scholar
• 47  Victor FC, Gottlieb AB, Menter A: Changing paradigms in dermatology: tumor necrosis factor α (TNFα) blockade in psoriasis and psoriatic arthritis. Clin. Dermatol.21,392–397 (2003).
  MedlineGoogle Scholar
• 48  Tak PP, Taylor PC, Breedveld FC et al.: Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum.39(7),1077–1081 (1996).
  Medline CASGoogle Scholar
• 49  Paleolog EM, Hunt M, Elliott MJ et al.: Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritis. Arthritis Rheum.39(7),1082–1091 (1996).
  Medline CASGoogle Scholar
• 50  Klimiuk PA, Sierakowski S, Domyslawska I et al.: Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab. Arch. Immunol. Ther. Exp. (Warsz).52(1),36–42 (2004).
  Medline CASGoogle Scholar
• 51  Goedkoop AY, Kraan MC, Teunissen MB et al.: Early effects of tumour necrosis factor α blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann. Rheum. Dis.63(7),769–773 (2004).
  Medline CASGoogle Scholar
• 52  Miyara M, Sakaguchi S: Natural regulatory T cells: mechanisms of suppression. Trends Mol. Med.13(3),108–116 (2007).
  Medline CASGoogle Scholar
• 53  Lipsky PE, van der Heijde DMFM, St Clair EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med.343,1594–1602 (2000).
  Medline CASGoogle Scholar
• 54  Valencia X, Stephens G, Goldbach-Mansky R et al.: TNF downmodulates the function of human CD4⁺CD25^hi T-regulatory cells. Blood108,253–261 (2006).
  Medline CASGoogle Scholar
• 55  Ehrenstein MR, Evans JG, Singh A et al.: Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J. Exp. Med.200(3),277–285 (2004).
  Medline CASGoogle Scholar
• 56  Nadkarni S, Mauri C, Ehrenstein MR: Anti-TNF-α therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-β. J. Exp. Med.204(1),33–39 (2007).
  Medline CASGoogle Scholar
• 57  Scallon B, Cai A, Solowski N et al.: Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exp. Ther.301,418–426 (2002).
  Medline CASGoogle Scholar
• 58  Scallon BJ, Moore MA, Trinh H et al.: Ghrayeb, chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine7,251–259 (1995).
  Medline CASGoogle Scholar
• 59  Gramlick A, Fossati G, Nesbitt AM et al.: Neutralization of soluble and membrane tumor necrosis factor-α (TNF-α) by infliximab, adalimumab, or certolizumab pegol using P55 or P75 TNF-α receptor-specific bioassays, Gastroenterology130(4),A697 (2006).
  Google Scholar
• 60  Nesbitt AM, Fossati G, Brown DT: Comparison of certolizumab pegol, etanercept, adalimumab, and infliximab: effect on lipopolysaccharide-induced cytokine production by human peripheral blood monocytes. Am. J. Gastroenterol.101(Suppl. 2),S420–S470 (2006).
  MedlineGoogle Scholar
• 61  Bruns H, Meinken C, Schauenberg P, et al.: Anti-TNF immunotherapy reduces CD8⁺ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J. Clin. Invest.119(5),1167–1177 (2009).
  Medline CASGoogle Scholar
• 62  Eissner G, Kolch W, Scheurich P: Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev.15,353–366 (2004).
  Medline CASGoogle Scholar
• 63  Harashima SI, Horiuchi T, Hatta N et al.: Outside-to-inside signal through the membrane TNF-α induces E-selectin (CD62E) expression on activated human CD4⁺ T cells. J. Immunol.166,130–136 (2001).
  Medline CASGoogle Scholar
• 64  Mitoma H, Horiuchi T, Hatta N et al.: Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α. Gastroenterology128,376–392 (2005).
  Medline CASGoogle Scholar
• 65  Nesbitt A, Fossati G, Bergin M et al.: Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor α agents. Inflamm. Bowel Dis.13(11),1323–1332 (2007).
  MedlineGoogle Scholar
• 66  Kyle S, Chandler D, Griffiths CE et al. Guideline for anti-TNF-α therapy in psoriatic arthritis. Rheumatology (Oxford)44,390–397 (2005).
  Medline CASGoogle Scholar
• 67  Sadowski DC, Bernstein CN, Bitton A, Croitoru K, Fedorak RN, Griffiths A; CAG Crohn’s Consensus Group: Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of tumour necrosis factor-α antagonist therapy in Crohn’s disease. Can. J. Gastroenterol.23(3),185–202 (2009).
  Medline CASGoogle Scholar
• 68  Fautrel B, Pham T, Mouterde G et al.: Recommendations of the French Society for Rheumatology regarding TNF-α antagonist therapy in patients with rheumatoid arthritis. Joint Bone Spine74(6),627–637 (2007).
  Medline CASGoogle Scholar
• 69  Rogan MP, Thomas K: Fatal miliary coccidioidomycosis in a patient receiving infliximab therapy: a case report. J. Med. Case Reports1,79 (2007).
  MedlineGoogle Scholar
• 70  Inanc N, Direskeneli H: Serious infections under treatment with TNF-α antagonists compared to traditional DMARDs in patients with rheumatoid arthritis. Rheumatol. Int.27(1),67–71 (2006).
  Medline CASGoogle Scholar
• 71  Toussirot E, Streit G, Wendling D: Infectious complications with anti-TNFα therapy in rheumatic diseases: a review. Recent Pat. Inflamm. Allergy Drug Discov.1(1),39–47 (2007).
  Medline CASGoogle Scholar
• 72  Haroon M, Bond U, Phelan M: Sinusitis: a possible link with adalimumab. Clin. Rheumatol.27(9),1189–1190 (2008).
  MedlineGoogle Scholar
• 73  Estrada S, García-Campos F, Calderón R, Delgado E, Bengoa R, Enciso C: Pneumocystis jiroveci (carinii) pneumonia following a second infusion of infliximab in a patient with ulcerative colitis. Inflamm. Bowel Dis.15(2),315–316 (2009).
  MedlineGoogle Scholar
• 74  Komano Y, Harigai M, Koike R et al.: Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case–control study of 21 patients. Arthritis Rheum.61(3),305–312 (2009).
  Medline CASGoogle Scholar
• 75  Elbek O, Uyar M, Aydin N et al.: Increased risk of tuberculosis in patients treated with antitumor necrosis factor-α. Clin. Rheumatol.28(4),421–426 (2009).
  MedlineGoogle Scholar
• 76  Endean AL, Barry SM, Young-Min SA: Possible miliary tuberculosis during adalimumab therapy with negative γ-IFN release assays. Rheumatology (Oxford)48(3),319–320 (2009).
  Medline CASGoogle Scholar
• 77  Antolín J, Azahara M, Hernández C, Blanco M, Mao L, Cigüenza R: Tuberculous peritonitis after treatment with adalimumab. Scand. J. Infect. Dis.40(8),677–678 (2008).
  MedlineGoogle Scholar
• 78  Galati V, Grilli E, Busi Rizzi E, Prantera C, Petrosillo N: Cerebral tubercular lesions in a patient treated with infliximab for Crohn’s disease. J. Neurol.255(12),1981–1982 (2008).
  Medline CASGoogle Scholar
• 79  Malkin J, Shrimpton A, Wiselka M, Barer MR, Duddridge M, Perera N: Olecranon bursitis secondary to Mycobacterium kansasii infection in a patient receiving infliximab for Behcet’s disease. J. Med. Microbiol.58(Pt 3),371–373 (2009).
  MedlineGoogle Scholar
• 80  Martín-Aspas A, Guerrero-Sánchez F, García-Martos P, González-Moya E, Medina-Varo F, Girón González JÁ: Bilateral pneumonia by Mycobacterium aurum in a patient receiving infliximab therapy. J. Infect.57(2),167–169 (2008).
  MedlineGoogle Scholar
• 81  Micekova D, Solovic I, Rovensky J et al.: Effectiveness of the combination of a whole-blood interferon-γ assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum.59(6),800–806 (2008).
  MedlineGoogle Scholar
• 82  Fernández-Guerrero ML, Esteban J, Acebes C, Górgolas M: Failure of isoniazid chemoprophylaxis during infliximab therapy. Emerg. Infect. Dis.13(9),1428–1429 (2007).
  Medline CASGoogle Scholar
• 83  Ledingham J, Deighton C: Update on the British Society for Rheumatology guidelines for prescribing TNF-α blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford)45(6),649–652 (2006).
  MedlineGoogle Scholar
• 84  Oberstein EM, Kromo O, Tozman EC: Type I reaction of Hansen’s disease with exposure to adalimumab: a case report. Arthritis Rheum.59(7),1040–1043 (2008).
  MedlineGoogle Scholar
• 85  Narayana N, Gifford R, Giannini P, Casey J: Oral histoplasmosis: an unusual presentation. Head Neck31(2),274–277 (2009).
  MedlineGoogle Scholar
• 86  Manz M, Beglinger C, Vavricka SR: Fatal invasive pulmonary aspergillosis associated with adalimumab therapy. Gut58(1),149 (2009); comment on: Gut56(9),1232–1239 (2007).
  Medline CASGoogle Scholar
• 87  Galandiuk S, Davis BR: Infliximab-induced disseminated histoplasmosis in a patient with Crohn’s disease. Nat. Clin. Pract. Gastroenterol. Hepatol.5(5),283–287 (2008).
  MedlineGoogle Scholar
• 88  Kozic H, Riggs K, Ringpfeil F, Lee JB: Disseminated Cryptococcus neoformans after treatment with infliximab for rheumatoid arthritis. J. Am. Acad. Dermatol.58(5 Suppl. 1),S95–S96 (2008).
  MedlineGoogle Scholar
• 89  Odessey E, Cohn A, Beaman K, Schechter L: Invasive mucormycosis of the maxillary sinus: extensive destruction with an indolent presentation. Surg. Infect.9(1),91–98 (2008).
  MedlineGoogle Scholar
• 90  Saad AA, Symmons DP, Noyce PR, Ashcroft DM: Risks and benefits of tumor necrosis factor-α inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J. Rheumatol.35(5),883–890 (2008).
  Medline CASGoogle Scholar
• 91  Tektonidou MG, Skopouli FN: Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection? Clin. Rheumatol.27(4),541–542 (2008).
  MedlineGoogle Scholar
• 92  Pizzorni C, Secchi ME, Cutolo M: [Leishmaniasis in rheumatoid arthritis.] Reumatismo59(3),235–239 (2007).
  Medline CASGoogle Scholar
• 93  Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA295(19),2275–2285 (2006).
  Medline CASGoogle Scholar
• 94  Wölbing F, Fierlbeck G, Hötzenecker W, Schaller M, Röcken M: Septic shock after treatment of Pyoderma gangrenosum with infliximab. Acta Derm. Venereol.89(1),93–94 (2009).
  MedlineGoogle Scholar
• 95  Benítez-Macías JF, García-Gil D, Brun-Romero FM: [Fatal phenmococcal sepsis in patient with hidradenitis suppurative treated with inflixumeb.] Med. Clin. (Barc.)131(20),799 (2008).
  MedlineGoogle Scholar
• 96  Choi KH, Yoo WH: Necrotizing fasciitis in a patient treated with etanercept for dermatomyositis. Rheumatol. Int.29(4),463–466 (2009).
  MedlineGoogle Scholar
• 97  Darabi K, Jaiswal R, Hostetler S, Bechtel M, Zirwas M: Infectious complications in patients with psoriasis and rheumatoid arthritis treated with antitumor necrosis factor agents and methotrexate. J. Drugs Dermatol.8(2),175–178 (2009).
  MedlineGoogle Scholar
• 98  Williams G, Khan AA, Schweiger F: Listeria meningitis complicating infliximab treatment for Crohn’s disease. Can. J. Infect. Dis. Med. Microbiol.16(5),289–292 (2005).
  MedlineGoogle Scholar
• 99  Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF: Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin. Gastroenterol. Hepatol.6(6),644–653 (2008).
  Medline CASGoogle Scholar
• 100  Nobile S, Catassi C, Felici L: Herpes zoster infection followed by Henoch–Schönlein purpura in a girl receiving infliximab for ulcerative colitis. J. Clin. Rheumatol.15(2),101 (2009); comment on: J. Clin. Rheumatol.12(5),249–251 (2006).
  MedlineGoogle Scholar
• 101  Strangfeld A, Listing J, Herzer P et al.: Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents. JAMA301(7),737–744 (2009); comment on: JAMA301(7),774–775 (2009).
  Medline CASGoogle Scholar
• 102  Wendling D, Streit G, Toussirot E, Prati C: Herpes zoster in patients taking TNF-α antagonists for chronic inflammatory joint disease. Joint Bone Spine75(5),540–543 (2008).
  Medline CASGoogle Scholar
• 103  Domm S, Cinatl J, Mrowietz U: The impact of treatment with tumour necrosis factor-α antagonists on the course of chronic viral infections: a review of the literature. Br. J. Dermatol.159(6),1217–1228 (2008).
  Medline CASGoogle Scholar
• 104  Becart S, Segaert S: Recurrent varicella in an adult psoriasis patient treated with etanercept. Dermatology217(3),260–261 (2008).
  Medline CASGoogle Scholar
• 105  Justice EA, Khan SY, Logan S, Jobanputra P: Disseminated cutaneous herpes simplex virus-1 in a woman with rheumatoid arthritis receiving INFLIXIMAB: a case report. J. Med. Case Reports2,282 (2008).
  MedlineGoogle Scholar
• 106  Komatsuda A, Wakui H, Nimura T, Sawada K: Reversible infliximab-related lymphoproliferative disorder associated with Epstein–Barr virus in a patient with rheumatoid arthritis. Mod. Rheumatol.18(3),315–318 (2008).
  Medline CASGoogle Scholar
• 107  Ojiro K, Naganuma M, Ebinuma H et al.: Reactivation of hepatitis B in a patient with Crohn’s disease treated using infliximab. J. Gastroenterol.43(5),397–401 (2008).
  MedlineGoogle Scholar
• 108  Favalli EG, Desiati F, Atzeni F et al.: Serious infections during anti-TNFα treatment in rheumatoid arthritis patients. Autoimmun. Rev.8(3),266–273 (2009).
  Medline CASGoogle Scholar
• 109  Menter A, Reich K, Gottlieb AB et al.: Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations. J. Drugs Dermatol.7(12),1137–1146 (2008).
  MedlineGoogle Scholar
• 110  Callen JP: Immunomodulators. In: Dermatology (2nd Edition). Bologna J, Jorizzo JL, Rapini RP (Eds). Mosby, UK 1973–1990 (2008).
  Google Scholar
• 111  Eitstrom Smedby K, Vajdic CM, Falster M et al.: Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the Interlymph Consortium. Blood111(8),4029–4038 (2008).
  MedlineGoogle Scholar
• 112  de Vries HS, van Oijen MG, de Jong DJ: Serious events with infliximab in patients with inflammatory bowel disease: a 9 year cohort study in The Netherlands. Drug Saf.31(12),1135–1144 (2008).
  MedlineGoogle Scholar
• 113  Mackey AC, Green L, Leptak C, Avigan M: Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J. Pediatr. Gastroenterol. Nutr.48(3),386–388 (2009); comment on: J. Pediatr. Gastroenterol. Nutr.44(2),265–267 (2007).
  MedlineGoogle Scholar
• 114  Ganguly S: Leukemic phase of follicular lymphoma after treatment with etanercept in a patient with psoriasis. Am. J. Clin. Dermatol.10(2),125–126 (2009).
  MedlineGoogle Scholar
• 115  Comte C, Guilhou JJ, Guillot B, Dereure O: Rapid onset and fatal outcome of two squamous cell carcinomas of the genitalia in a patient treated with etanercept for cutaneous psoriasis. Dermatology217(3),284–285 (2008).
  MedlineGoogle Scholar
• 116  Chuang GS, Wasserman DI, Byers HR, Demierre MF: Hypopigmented T-cell dyscrasia evolving to hypopigmented mycosis fungoides during etanercept therapy. J. Am. Acad. Dermatol.59(Suppl. 5),S121–S122 (2008).
  MedlineGoogle Scholar
• 117  Hurley MY, George MN, Leonardi CL, Frater JL: A transient benign lymph node-based proliferation of T-cells simulating non-Hodgkin lymphoma in a patient with psoriasis treated with tumor necrosis factor α and CD11a antagonists. Diagn. Pathol.3,13 (2008).
  MedlineGoogle Scholar
• 118  Aksu K, Donmez A, Ertan Y et al.: Hodgkin’s lymphoma following treatment with etanercept in ankylosing spondylitis. Rheumatol. Int.28(2),185–187 (2007).
  MedlineGoogle Scholar
• 119  Weimer LH, Sachdev N: Update on medication-induced peripheral neuropathy. Curr. Neurol. Neurosci. Rep.9(1),69–75 (2009).
  Medline CASGoogle Scholar
• 120  Makol A, Grover M: Adalimumab induced mononeuritis multiplex in a patient with refractory rheumatoid arthritis: a case report. Cases J.1(1),287 (2008).
  MedlineGoogle Scholar
• 121  Zamvar V, Sugarman ID, Tawfik RF, Macmullen-Price J, Puntis JW: Posterior reversible encephalopathy syndrome following infliximab infusion. J. Pediatr. Gastroenterol. Nutr.48(1),102–105 (2009).
  MedlineGoogle Scholar
• 122  Kameda T, Dobashi H, Kittaka K et al.: A case of rheumatoid arthritis complicated by demyelination in both cerebral cortex and spinal cord during etanercept therapy. Mod. Rheumatol.18(4),399–402 (2008).
  MedlineGoogle Scholar
• 123  Booker MJ, Flint J, Saravana S: Aseptic meningitis in a patient taking etanercept for rheumatoid arthritis: a case report. Cases J.1(1),364 (2008).
  MedlineGoogle Scholar
• 124  Hooper DR, Tarnopolsky MA, Baker SK: Lewis–Sumner syndrome associated with infliximab therapy in rheumatoid arthritis. Muscle Nerve38(4),1318–1325 (2008).
  Medline CASGoogle Scholar
• 125  Russo MA, Dorahy DJ: Complex regional pain syndrome after infliximab infusion. J. Pain Symptom Manage.37(3),E9–E10 (2009); comment on: J. Pain Symptom Manage.36(3),E2–E4 (2008).
  MedlineGoogle Scholar
• 126  Stübgen JP: Tumor necrosis factor-α antagonists and neuropathy. Muscle Nerve37(3),281–292 (2008).
  Medline CASGoogle Scholar
• 127  Pfueller CF, Seipelt E, Zipp F, Paul F: Multiple sclerosis following etanercept treatment for ankylosing spondylitis. Scand. J. Rheumatol.37(5),397–399 (2008).
  Medline CASGoogle Scholar
• 128  Gonnet-Gracia C, Barnetche T, Richez C, Blanco P, Dehais J, Schaeverbeke T: Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-α blockers. Clin. Exp. Rheumatol.26(3),401–407 (2008).
  Medline CASGoogle Scholar
• 129  Martín JM, Ricart JM, Alcácer J, Rausell N, Arana G: Adalimumab-induced lupus erythematosus. Lupus17(7),676–678 (2008).
  Medline CASGoogle Scholar
• 130  Mounach A, Ghazi M, Nouijai A et al.: Drug-induced lupus-like syndrome in ankylosing spondylitis treated with infliximab. Clin. Exp. Rheumatol.26(6),1116–1118 (2008).
  Medline CASGoogle Scholar
• 131  Benucci M, Nenci G, Cappelletti C, Manfredi M: Lupus like syndrome induced by treatment with anti TNFα (infliximab): report of three cases. Recenti. Prog. Med.99(7–8),363–366 (2008).
  MedlineGoogle Scholar
• 132  Cuchacovich R, Espinoza CG, Virk Z, Espinoza LR: Biologic therapy (TNF-α antagonists)-induced psoriasis: a cytokine imbalance between TNF-α and IFN-α? J. Clin. Rheumatol.14(6),353–356 (2008).
  MedlineGoogle Scholar
• 133  Chan CY, Browning JC, Larsen F, Hsu S: Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis. Dermatol. Online J.14(9),12 (2008).
  MedlineGoogle Scholar
• 134  Costa-Romero M, Coto-Segura P, Suarez-Saavedra S, Ramos-Polo E, Santos-Juanes J: Guttate psoriasis induced by infliximab in a child with Crohn’s disease. Inflamm. Bowel Dis.14(10),1462–1463 (2008).
  MedlineGoogle Scholar
• 135  Monteagudo Sánchez B, Cabanillas M, Ortiz- S, Gallego-Ojea JC: [Infliximab-induced pustular psoriasis in a patient with Crohn’s disease.] Gastroenterol. Hepatol.32(3),175–176 (2009).
  MedlineGoogle Scholar
• 136  Wermuth J, Kind F, Steuerwald M: Palmoplantar pustulosis and acrodermatitis in a patient treated with infliximab for Crohn’s sacroiliitis. Clin. Gastroenterol. Hepatol.7(2),A28 (2009).
  MedlineGoogle Scholar
• 137  Harris MD, Richards R: First case report of adalimumab-induced psoriasis in Crohn’s disease. Am. J. Gastroenterol.104(3),792–793 (2009).
  MedlineGoogle Scholar
• 138  Richetta A, Mattozzi C, Carlomagno V et al.: A case of infliximab-induced psoriasis. Dermatol. Online J.14(11),9 (2008).
  Medline CASGoogle Scholar
• 139  Harrison MJ, Dixon WG, Watson KD et al.: Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis.68(2),209–215 (2009).
  Medline CASGoogle Scholar
• 140  Collamer AN, Guerrero KT, Henning JS, Battafarano DF: Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum.59(7),996–1001 (2008).
  Medline CASGoogle Scholar
• 141  Levine SD, Robinson M, Honda K, Nedorost S: Interstitial granulomatous dermatitis in a patient with rheumatoid arthritis on etanercept. Cutis83(1),50 (2009).
  MedlineGoogle Scholar
• 142  Deng A, Harvey V, Sina B et al.: Intersticial granulomatous dermatitis associated with the use of tumor necrosis factor-α inhibitors. Arch. Dermatol.142,198–202 (2006).
  MedlineGoogle Scholar
• 143  Roé E, Puig L, Corella F, García-Navarro X, Alomar A: Cutaneous adverse effects of biological therapies for psoriasis. Eur. J. Dermatol.18(6),693–699 (2008).
  MedlineGoogle Scholar
• 144  Mangat P, Whittle S, Cleland L: Digital vasculitis: a late complication of anti-tumour necrosis factor α therapy. Clin. Rheumatol.27(12),1593–1595 (2008).
  MedlineGoogle Scholar
• 145  Lahbabi I, Adamski H, Le Jean S, Cannieux V, Polard E, Chevrant-Breton J: Neutropenia and thrombocytopenia in a patient presenting psoriasis treated with etanercept. Ann. Dermatol. Venereol.135(5),409–410 (2008).
  Medline CASGoogle Scholar
• 146  de Oliveira JP, Levy A, Morel P, Guibal F: Severe neutrophilia induced by infliximab for psoriasis. Br. J. Dermatol.158(1),200–201 (2008).
  Medline CASGoogle Scholar
• 147  Hatakeyama T, Komatsuda A, Matsuda A et al.: Renal amyloidosis associated with extracapillary glomerulonephritis and vasculitis in a patient with inflammatory bowel disease treated with infliximab. Clin. Nephrol.70(3),240–244 (2008).
  Medline CASGoogle Scholar
• 148  Portuesi MG, Perosa P: Neprhrotic syndrome in a patient with rheumatoid arthritis treated with adalimumab: a case report. Reumatismo60(1),61–63 (2008).
  Medline CASGoogle Scholar
• 149  Leak AM, Rincon-Aznar B: Hepatotoxicity associated with etanercept in psoriatic arthritis. J. Rheumatol.35(11),2286–2287 (2008).
  MedlineGoogle Scholar
• 150  Fathalla BM, Goldsmith DP, Pascasio JM, Baldridge A: Development of autoimmune hepatitis in a child with systemic-onset juvenile idiopathic arthritis during therapy with etanercept. J. Clin. Rheumatol.14(5),297–298 (2008).
  MedlineGoogle Scholar
• 151  García Simon MS, Saliente Callén S, López Avila A, Rabell Iñigo S: [Hepatic cytolysis from infliximab.] Farm. Hosp.32(4),250–252 (2008).
  Medline CASGoogle Scholar
• 152  Yazisiz V, Avci AB, Erbasan F, Yildirim B, Terzioglu E: Development of Crohn’s disease following anti-tumour necrosis factor therapy (etanercept). Colorectal Dis.10(9),953–954 (2008).
  Medline CASGoogle Scholar
• 153  Lazzerini PE, Acampa M, Hammoud M et al.: Arrhythmic risk during acute infusion of infliximab: a prospective, single-blind, placebo-controlled, crossover study in patients with chronic arthritis. J. Rheumatol.35(10),1958–1965 (2008).
  Medline CASGoogle Scholar
• 154  Nishida K, Okada Y, Nawata M, Saito K, Tanaka Y: Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-α antibody. Endocr. J.55(1),213–216 (2008).
  Medline CASGoogle Scholar
• 155  Burke JP, Kelleher B, Ramadan S, Quinlan M, Sugrue D, O’Donovan MA: Pericarditis as a complication of infliximab therapy in Crohn’s disease. Inflamm. Bowel Dis.14(3),428–429 (2008).
  Medline CASGoogle Scholar
• 156  Díez Piña JM, Vázquez Gómez O, Mayoralas Alises S, García Jiménez JD, Alvaro Alvarez D, Rodríguez Bolado MP: Etanercept as a possible trigger of fatal pulmonary fibrosis. Arch. Bronconeumol.44(7),393–395 (2008).
  MedlineGoogle Scholar
• 157  Janssen R, Krivokuca I, Kruize AA, Koenderman L, Lammers JW: Adalimumab-induced bronchospasm: not a class effect. Thorax63(5),472–473 (2008).
  CASGoogle Scholar
• 158  Hejazi R, Colombel JF, Peyrin-Biroulet L: Retrobulbar optic neuritis during infliximab treatment for ulcerative colitis. Gastroenterol. Clin. Biol.32(2),162–163 (2008).
  Medline CASGoogle Scholar
• 159  Veerappan SG, Kennedy M, O’Morain CA, Ryan BM: Retinal vein thrombosis following infliximab treatment for severe left-sided ulcerative colitis. Eur. J. Gastroenterol. Hepatol.20(6),588–589 (2008).
  MedlineGoogle Scholar
• 160  Stinco G, Piccirillo F, Patrone P: Hypertriglyceridaemia during treatment with adalimumab in psoriatic arthritis. Br. J. Dermatol.157(6),1273–1274 (2007).
  Medline CASGoogle Scholar
• 161  Dryden GW: Overview of biologic therapy for Crohn’s diseas. Expert Opin. Biol. Ther.9(8),967–974 (2009).
  Medline CASGoogle Scholar
• 162  Menter A: The status of biologic therapies in the treatment of moderate to severe psoriasis. Cutis84(Suppl. 4),14–24 (2009).
  MedlineGoogle Scholar
• 163  Arnauld L, Haroche J, Piette JC, Amoura Z: [The immunomodulatory biotherapies of the future: what perspectives?]. Presse Med.38,749–760 (2009).
  MedlineGoogle Scholar
• 164  Ohno S, Nakamura S, Hori S et al.: Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet disease with refractory uveoretinitis. J. Rheumatol.31,1362–1368 (2004).
  Medline CASGoogle Scholar
• 165  Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M: Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease. Br. J. Ophthalmol.94(3),284–288 (2010).
  MedlineGoogle Scholar
• 166  Sitapati AM, Kao CL, Cachay ER et al.: Treatment of HIV-related inflammatory cerebral cryptococcoma with adalimumab. Clin. Infect. Dis.50,E7–E10 (2010).
  MedlineGoogle Scholar